[Quality of life of patients with multiple sclerosis in the Smolensk region].
Обработка статьи · этапы, ошибки и управление
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Maslova N N, Nikitenkova V E, Gapeeva U E, Shchukin P A
Аннотация
MATERIAL AND METHODS: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
RESULTS: The results of the survey showed a decrease in QoL of MS patients compared to the control group. The level of disability and the duration of the disease have the greatest impact on QoL. Factors such as sex, MS DMT, and the socio-economic status of the patient have less impact on QoL.
CONCLUSION: Given the priority impact of the level of disability on QoL of the patient, there is a need for earlier prescription of DMT to stop the progression of the disease.
Оригинал публикации
[Quality of life of patients with multiple sclerosis in the Smolensk region].
OBJECTIVE: To study the quality of life (QoL) of patients with multiple sclerosis (MS) in the Smolensk region who receive MS disease-modifying therapies (DMT).
MATERIAL AND METHODS: The study included 37 patients receiving MS DMT. The 36-Item Short Form Health Survey (SF-36), the Multiple sclerosis Quality of Life (MusiQol), the Hamilton Depression Rating Scale, a scale of satisfaction with treatment, the Fatigue Severity Scale were administered.
RESULTS: The results of the survey showed a decrease in QoL of MS patients compared to the control group. The level of disability and the duration of the disease have the greatest impact on QoL. Factors such as sex, MS DMT, and the socio-economic status of the patient have less impact on QoL.
CONCLUSION: Given the priority impact of the level of disability on QoL of the patient, there is a need for earlier prescription of DMT to stop the progression of the disease.